Analyst Ratings for Aegerion Pharmaceuticals (AEGR) [Buys]
AEGR Rating Summary
AEGR Price Target Summary
- Highest: $85.00 (Deutsche Bank)
- Lowest: $21.00 (ThinkEquity)
- Average: $39.00
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$39.00 (-34.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/5/2013 | BofA/Merrill Lynch | New Coverage | Buy (N/A) |
39.00 (N/A) |
32.52 | 59.35 | 82.5% | Details |
| 2/11/2013 | Lazard Capital | Upgrade | Buy (Hold) |
N/A (N/A) |
26.51 | 59.35 | 123.88% | Details |
| 1/3/2013 | Janney Montgomery Scott | New Coverage | Buy (N/A) |
30.00 (N/A) |
27.24 | 59.35 | 117.88% | Details |
| 12/21/2012 | Cowen | New Coverage | Outperform (N/A) |
N/A (N/A) |
24.62 | 59.35 | 141.06% | Details |
| 10/12/2012 | Capstone Investments | New Coverage | Buy (N/A) |
21.00 (N/A) |
13.98 | 59.35 | 324.54% | Details |
| 10/3/2012 | JPMorgan | New Coverage | Overweight (N/A) |
22.00 (N/A) |
14.93 | 59.35 | 297.52% | Details |
| 6/29/2012 | ThinkEquity | New Coverage | Buy (N/A) |
21.00 (N/A) |
14.22 | 59.35 | 317.37% | Details |
| 5/22/2012 | Needham & Company » Updated 10/18/2012 |
New Coverage | Buy (N/A) |
30.00 (22.00) |
14.48 | 59.35 | 309.88% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 6/6/2012 |
New Coverage | Buy (N/A) |
27.00 (N/A) |
14.00 | 59.35 | 323.93% | Details |
| 11/9/2011 | Deutsche Bank » Updated 5/16/2013 |
New Coverage | Buy (N/A) |
85.00 (52.00) |
14.97 | 59.35 | 296.46% | Details |
| 10/10/2011 | Jefferies » Updated 5/10/2013 |
New Coverage | Buy (N/A) |
50.00 (46.00) |
13.14 | 59.35 | 351.67% | Details |
| 6/28/2011 | Global Hunter Securities | New Coverage | Buy (N/A) |
N/A (N/A) |
15.29 | 59.35 | 288.16% | Details |
| 12/6/2010 | Collins Stewart | Upgrade | Buy (N/A) |
N/A (N/A) |
10.99 | 59.35 | 440.04% | Details |
| 12/2/2010 | Leerink Swann » Updated 5/16/2013 |
New Coverage | Outperform (N/A) |
65.00 (50.00) |
10.84 | 59.35 | 447.51% | Details |
